{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:45:55Z","timestamp":1777556755631,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.lungcan.2023.107288","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T03:46:48Z","timestamp":1688442408000},"page":"107288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Safety and efficacy of atezolizumab in Chinese patients with previously treated locally advanced or metastatic non-small cell lung cancer: An open-label, single-arm, multicenter study"],"prefix":"10.1016","volume":"183","author":[{"given":"Yanjun","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongqing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiannan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2023.107288_b0005","unstructured":"Global Cancer Observatory. China Fact Sheet. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/160-china-fact-sheets.pdf, 2020 (accessed 11 April 2023)."},{"key":"10.1016\/j.lungcan.2023.107288_b0010","unstructured":"American Cancer Society. About Lung Cancer. https:\/\/www.cancer.org\/cancer\/lung-cancer\/about\/what-is.html, 2019 (accessed 11 April 2023)."},{"key":"10.1016\/j.lungcan.2023.107288_b0015","first-page":"122","article-title":"Treatment of advanced non small cell lung cancer","volume":"3","author":"Bareschino","year":"2011","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2023.107288_b0020","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.7150\/jca.57334","article-title":"A snapshot of the PD-1\/PD-L1 pathway","volume":"12","author":"Ghosh","year":"2012","journal-title":"J. Cancer"},{"key":"10.1016\/j.lungcan.2023.107288_b0025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/JTO.0b013e3181622c17","article-title":"Prevalence of poor performance status in lung cancer patients: implications for research","volume":"3","author":"Lilenbaum","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.107288_b0030","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1200\/JCO.18.02118","article-title":"Immunotherapy in non-small-cell lung cancer patients with performance status 2: clinical decision making with scant evidence","volume":"37","author":"Passaro","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107288_b0035","doi-asserted-by":"crossref","first-page":"S677","DOI":"10.1016\/j.jtho.2016.11.884","article-title":"Prevalence of autoimmune disease in US veterans with non-small cell lung cancer (NSCLC)","volume":"12","author":"Patel","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.107288_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.11.010","article-title":"Immune checkpoint blockade for non-small cell lung cancer: what is the role in the special populations?","volume":"125","author":"Califano","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2023.107288_b0045","doi-asserted-by":"crossref","unstructured":"A. Rittmeyer, F. Barlesi, D. Waterkamp, K. Park, F. Ciardiello, J. von Pawel, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389 (2017) 255\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(16)32517-X. Erratum in: Lancet 389 (2017) e5. https:\/\/doi.org\/10.1016\/S0140-6736(17)30904-2.","DOI":"10.1016\/S0140-6736(16)32517-X"},{"issue":"10030","key":"10.1016\/j.lungcan.2023.107288_b0050","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2023.107288_b0055","doi-asserted-by":"crossref","unstructured":"A. Ardizzoni, S. Azevedo, B. Rubio-Viqueira, D. Rodr\u00edguez-Abreu, J. Alatorre-Alexander, H.J.M. Smit, et al. Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer. J Immunother Cancer 9 (2021) e001865. https:\/\/doi.org\/10.1136\/jitc-2020-001865.","DOI":"10.1136\/jitc-2020-001865"},{"key":"10.1016\/j.lungcan.2023.107288_b0060","article-title":"Effectiveness and safety of atezolizumab monotherapy in previously treated Japanese patients with unresectable advanced or recurrent non-small cell lung cancer: a multicenter, prospective, observational study (J-TAIL)","volume":"4","author":"Miura","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.lungcan.2023.107288_b0065","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00432-020-03444-y","article-title":"Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China","volume":"147","author":"Zheng","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.lungcan.2023.107288_b0070","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.7150\/jca.63003","article-title":"PD-L1 expression in chinese patients with advanced non-small cell lung cancer (nsclc): a multi-center retrospective observational study","volume":"12","author":"Yang","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.lungcan.2023.107288_b0075","unstructured":"HIGHLIGHTS OF PRESCRIBING INFORMATION TECENTRIQ\u00ae (atezolizumab) injection, for intravenous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761034s042lbl.pdf, 2021 (accessed 11 April 2023)."},{"issue":"24","key":"10.1016\/j.lungcan.2023.107288_b0080","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1200\/JCO.2016.71.9476","article-title":"Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand-1-selected advanced non-small-cell lung cancer (BIRCH)","volume":"35","author":"Peters","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2023.107288_b0085","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.21037\/tlcr-22-360","article-title":"Efficacy, prognosis and safety analysis of anti-PD-1\/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study","volume":"11","author":"Yang","year":"2022","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2023.107288_b0090","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40164-021-00211-8","article-title":"Predictive biomarkers of anti-PD-1\/PD-L1 therapy in NSCLC","volume":"10","author":"Niu","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.lungcan.2023.107288_b0095","doi-asserted-by":"crossref","unstructured":"F. Li, C. Li, X. Cai, Z. Xie, L. Zhou, B. Cheng, et al. The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis. EClinicalMedicine 41 (2021) 101134. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101134.","DOI":"10.1016\/j.eclinm.2021.101134"},{"issue":"7","key":"10.1016\/j.lungcan.2023.107288_b0100","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","article-title":"Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing","volume":"36","author":"Rizvi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107288_b0105","doi-asserted-by":"crossref","unstructured":"F. Skoulidis, M.E. Goldberg, D.M. Greenawalt, M.D. Hellmann, M.M. Awad, J.F. Gainor, et al. STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov 8 (2018) 822\u201335. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0099.","DOI":"10.1158\/2159-8290.CD-18-0099"},{"key":"10.1016\/j.lungcan.2023.107288_b0110","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3390\/molecules26041083","article-title":"Regulation of ZMYND8 to treat cancer","volume":"26","author":"Chen","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.lungcan.2023.107288_b0115","doi-asserted-by":"crossref","unstructured":"F. de Miguel, R.D. Sharma, M.J. Pajares, L.M. Montuenga, A. Rubio, R. Pio. Identification of alternative splicing events regulated by the oncogenic factor SRSF1 in lung cancer. Cancer Res 74 (2014) 1105\u201315. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-1481.","DOI":"10.1158\/0008-5472.CAN-13-1481"},{"key":"10.1016\/j.lungcan.2023.107288_b0120","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1186\/s12885-015-1567-4","article-title":"XAB2 tagSNPs contribute to non-small cell lung cancer susceptibility in Chinese population","volume":"15","author":"Pei","year":"2015","journal-title":"BMC Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223008267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223008267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:04:28Z","timestamp":1759237468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223008267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":24,"alternative-id":["S0169500223008267"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107288","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of atezolizumab in Chinese patients with previously treated locally advanced or metastatic non-small cell lung cancer: An open-label, single-arm, multicenter study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107288"}}